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We agree with Thomson and Marshall (2013) that the
current prescribing of thiamine replacement therapy for
Wernicke’s Encephalopathy (WE) is ambiguous. In response
to their article, we also advocate that any consensus on ac-
curate thiamine treatment for WE should receive sufficient
international attention, since too many patients with WE are
currently inaccurately treated leading to unnecessary cases of
Korsakoff’s syndrome.
WE is a neurologic disease caused by thiamine (vitamin
B1) deficiency. Most patients with WE have a background of
chronic alcoholism and self-neglect (Sechi and Serra, 2007).
Importantly, WE is also a life-threatening condition associated
with a classic triad of acute neurological symptoms resembling
delirium: confusion, ataxia and eye-movement disorders
(McCormick et al., 2011; Wijnia and Oudman, 2013). Usually,
but not necessarily, patients will develop Korsakoff’s syndrome
characterized by chronic amnesia (Kopelman, 2002).
Slingedael offers a long-stay facility for patients with
Korsakoff’s syndrome in Rotterdam, The Netherlands. For triage
purposes, confused alcoholic patients with probable Wernicke–
Korsakoff’s syndrome related cognitive disorders are visited by
our physicians and psychologists, usually when they are inpati-
ents of general or psychiatric hospitals in the Rotterdam region
(~1.2 million inhabitants). In daily practice, we see very disap-
pointing results with respect to the quantity of patients that have
been appropriately treated with parenteral thiamine after admis-
sion to general or psychiatric hospitals. In fact, up to 90% of the
confused alcoholics that have been visited by members of our
team did not receive parenteral thiamine or received parenteral
thiamine just once. This while current Dutch recommendations
state that confused inpatients at risk of developing WE should
receive 250 mg i.m. or i.v. for at least 3 to 5 days; up to 500
mg i.v. for patients that have presumed WE (Van den Brink and
Jansen, 2009). Implementations of the guidelines have been
documented (Laurent and van der Schrieck - de Loos, 2009).
Therefore, we suggest that besides the clarity of the guide-
lines for treatment of WE also successful propagation for treat-
ment guidelines is necessary to prevent the detrimental effects
of unsuccessfully treated WE, namely Korsakoff’s syndrome.
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Abstract — In response to our suggestion to define substance use disorders
via ‘heavy use over time’, theoretical and conceptual issues, measurement
problems and implications for stigma and clinical practice were raised. With
respect to theoretical and conceptual issues, no other criterion has been
shown, which would improve the definition. Moreover, heavy use over time
is shown to be highly correlated with number of criteria in current DSM-5.
Measurement of heavy use over time is simple and while there will be some
underestimation or misrepresentation of actual levels in clinical practice, this
is not different from the status quo and measurement of current criteria. As
regards to stigma, research has shown that a truly dimensional concept can
help reduce stigma. In conclusion, ‘heavy use over time’ as a tangible
common denominator should be seriously considered as definition for sub-
stance use disorder.
We thank their authors for the four commentaries (Bradley
and Rubinsky, 2013; Heather, 2013; Rice, 2013; Saunders,
2013) on our suggestion to replace the current definitions of
substance dependence, use disorders, abuse and harmful use
by heavy use over time (Rehm et al., 2013a). Here, we
attempt to answer the points raised.
We see four major threads of discussion:
(a) Theoretical considerations that the essence of addic-
tions is different than currently defined by DSM and
ICD, and that the reformulation of heavy use over
time does not capture this point (Heather, 2013;
Saunders, 2013). This has a corollary that definitions
other than heavy use over time or heavy use over
time itself can better explain phenomena currently
associated with addictive behaviour (Bradley and
Rubinsky, 2013; Saunders, 2013).
(b) Problems with assessing heavy consumption over
time (Bradley and Rubinsky, 2013; Saunders, 2013).
(c) The usefulness of various concepts in reducing
stigma and in clinical practice (Bradley and
Rubinsky, 2013; Rice, 2013).
(d) Using heavy use as one of several criteria for defining
substance use disorders (Bradley and Rubinsky, 2013).
Starting with the theoretical considerations, we made our
arguments that almost all of what is currently conceptualized
under the heading of addiction or use disorders is a conse-
quence of heavy use over time (Rehm et al., 2013a).
Obviously, we used the current definitions of DSM IV, DSM
5 and ICD 10 as starting points. Both Rice and Saunders
note that these definitions have strayed quite far from the
single dimension of Saunders’ ‘internal drive’—the dimen-
sion that has been at the heart of the addiction concept as it
was invented in post-Enlightenment European cultures
(Levine, 1978). As Rice notes, DSM-5’s adoption of the
term ‘substance use disorder’ further cements this separation.
The addiction concept essentially puts forward an explan-
ation rather than a description: an explanation in terms of a
mysterious force driving behaviour. In the wake of the
St. Louis revolution in psychiatric nosology (Room, 1998),
psychiatric classification in the USA, and increasingly else-
where, has favoured description over the kind of psychodynam-
ic hypothesis represented by the classic addiction concept. An
explanation in terms of a mysterious force that cannot be fully
modelled in animal or neurobiological research can actually be
argued to be obstructive of scientific progress.
However, we agree that the situation ‘that some people
continue to use heavily despite knowing that their heavy use
is causing the negative consequences’ (Heather, 2013) is
worth continued investigation (see also (European
Monitoring Centre for Drugs and Drug Addiction, 2013),
where this concept is discussed in more detail), and in fact
one of the authors has emphasized the importance of investi-
gating automatically triggered or implicit processes in sub-
stance use disorders (Wiers and Stacy, 2006), exactly to
understand these psychological processes. However, while
these processes may be associated with the phenomenon of
continued heavy use they are not necessary to characterize it.
When we scrutinize the additional criteria proposed by the
commentators, we do not see a necessity to include other cri-
teria. For instance, all the correlations with other phenomena
that Saunders (2013) cites to demonstrate what he believes is
the core of addiction and its consequences are also true for
heavy use over time. To give an example, the amount of
heavy use over time is highly correlated with the number of
criteria fulfilled in current definitions; so, it is no surprise
that the correlations with outcomes are similar. To illustrate
this, we have undertaken a cross-tabulation of alcohol de-
pendence (last year) with level of use in the US National
Epidemiologic Survey on Alcohol and Related Conditions,
separated by treatment status (see Table 1). The more symp-
toms, the higher the consumption, with higher consumption
in people with lifetime treatment. Similarly, in a Catalonian
cohort of people treated for alcohol dependence, level of use,
sex and age ‘explained’ 94% of the variance of DSM III R
symptoms (for a description of the cohort (Gual et al.,
1999)). Significant associations were also found in the 2012
German Epidemiological Surveys of Substance Abuse, not
only for alcohol but also for tobacco, cannabis and cocaine
(data not shown; for a description see (Kraus et al., 2013)).
To conclude: all relevant effects used to demonstrate the evi-
dence for the usefulness of current criteria or for the number
of criteria as a measure of severity would be replicated by
levels of heavy use, as the two measures are highly corre-
lated. And as demonstrated in our original paper, the heavy
use over time concept better explained the relationships with
negative health outcomes (Rehm et al., 2013a).
Thus, as heavy use over time is the simplest concept, we
should just use this, unless there are clear indications that
other concepts better explain relevant phenomena that heavy
use over time cannot do. As for the understanding of an ‘in-
ternal drive’ (Saunders, 2013), we believe that it is enough
that heavy use over time leads to changes in the brain, which
Table 1. Average alcohol intake in grams per day by number of DSM-IV
criteria fulfilled for alcohol dependence (last year), by whether treated in
lifetime: from data of the US National Epidemiologic Survey on Alcohol
and Related Conditions (NESARC)
Gender
Number of criteria of DSM-IV for alcohol dependence
0 1 2 3 4 5 6 7
For people who have never been in treatment
Men 9.1 27.1 35.9 56.5 73.6 88.0 107.4 189.0
Women 4.1 13.6 19.8 23.6 48.5 56.7 108.8 114.5
Total 6.6 21.6 29.5 45.4 64.7 77.5 107.8 170.3
For people who have been in treatment in their lifetime
Men 20.6 35.2 98.2 75.2 109.1 124.2 119.8 214.1
Women 10.1 20.3 23.5 19.8 37.9 55.5 275.1 230.4
Total 17.5 31.7 77.9 61.5 91.2 104.7 165.1 218.3
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are linked to the behavioural expressions seen in ‘addicted’
people. We did not touch on whether such behaviour is vol-
untary or not, or under what circumstances it can be
reversed. Clearly, there are good examples for reversal of be-
haviour (e.g. of heavy heroin use over time in Vietnam veter-
ans (Robins, 1993)), whereas some changes in the brain such
as the reduction of the number of dopamine receptors in
people with heavy used over time may be more permanent
(Daglish et al., 2001; Volkow et al., 2011). However, it is im-
portant that consequences such as mortality are mainly linked
to the behaviour, i.e. to the level of heavy consumption over
time (Rehm et al., 2013a; Rehm and Roerecke, 2013;
Roerecke et al., 2013).
What about the examples given for socio-economic differ-
entials of consequences? The higher mortality risk associated
with heavy use can be found in all economic strata (for a
striking example: (Rossow and Amundsen, 1996)), but in
most studies, people in higher economic strata experience
less mortality and other consequences per alcohol consumed
than poorer people (Schmidt et al., 2010). This has to do
with better access to care, less interactions with other risk
factors (e.g. smoking, nutrition) and a better constellation of
environmental factors. Thus, across the whole range of dis-
eases and disorders, people with higher socio-economic
status tend to have lower mortality rates for the same beha-
viours or the same disease categories (Huisman et al., 2005;
Lantz et al., 2010). We do not see, however, why the current
definition of substance use disorders should have any advan-
tage in this respect.
As for measuring heavy use over time, the psychometric
qualities of measuring level of use for alcohol and tobacco
or frequency of use for other substances are no worse than
those that measure current criteria for substance use disor-
ders. Of course, in clinical interviews, some people may
underreport actual consumption, but the same is true for
current criteria. In addition, clinical practice rarely goes
through diagnostic criteria one by one anyway. In clinical
interviews, we imagine a process similar to high blood pres-
sure (see Nutt and Rehm, 2013). After having established
high blood pressure, doctors may ask about other signs, po-
tentially relevant behaviour (e.g., salt intake, behavioural
factors leading to higher BMI) or family disposition for car-
diovascular outcomes linked to high blood pressure such as
stroke. For heavy use over time, similar questions may be
asked. But this does not mean that such answers to such
questions would be used for establishing diagnoses of hyper-
tension or heavy use over time.
Finally, as for the cultural bias for loss of control, we pre-
sented evidence comparing Latvian and Italian survey
results, with multifold differences in alcohol dependence
prevalence, which in our view cannot be explained otherwise
(Rehm et al., 2013a). The differences between alcohol de-
pendence prevalence in Latvia and Italy are typical for a
North-South difference in Europe (Rehm et al., 2012; see
also Rehm et al., 2005): per litre of pure alcohol consumed
per capita, the prevalence of alcohol dependence in Baltic
and Nordic countries is 4–5 times the rate in Southern coun-
tries (the latter defined as comprising Cyprus, Greece, Italy,
Malta, Spain, Portugal). Associated indicators such as heavy
drinking prevalence or liver cirrhosis mortality do not show
multifold differences of this magnitude between regions
(Rehm et al., 2012; details for Latvia and Italia, see Rehm
et al., 2013a). While more research is necessary, we tried to
explain these differences by a cultural bias that would pre-
scribe that in Southern Europe one would not traditionally
admit to losing control over one’s drinking, whereas losing
control may be the very reason for many drinking occasions
in the Nordic and Baltic countries (Room, 2006, 2007).
Survey results tend to further support this reasoning:
Italians have much more drinking with meals (for level see
http://www.rssp.salute.gov.it/rssp2011/documenti/RSSP_2011_
Inglese_web.pdf; for comparative figures with Nordic and
other countries, see Leifman, 2002), i.e. in more controlled and
ritualistic settings (Marshall, 2005). Also, Italians drink com-
paratively less per occasion (Leifman, 2002), and while they
associate less negative consequences with their drinking
(Landberg, 2012), they indicated a high level of informal
control (Reitan, 2004). When looking for a definition of sub-
stance use disorders, these differences favour drinking over
time in our view, as this definition is better aligned with mor-
tality and health burden (Rehm et al., 2013b) than the current
measure, where you get multifold differences associated with
cultural variables more than with health burden.
Stigma is a major problem in all treatment of mental disor-
ders, but is particularly so with substance use disorders
(Üstün et al., 2001). There are no simple ways to deal with
stigma and exclusion in health care, but empirical research
has shown that stressing dimensional aspects of disease may
help reduce stigma (Schomerus et al., 2013). Thus, beliefs
that mental disorders are defined by putting thresholds on an
underlying continuum were associated with more positive
emotional reactions and less desire for social distance.
Unfortunately, for substance use disorders, such continuum
beliefs are not that pronounced. For instance, in a German
representative survey, only 27% of respondents believed in a
continuum for alcohol use disorders, a similar percentage as
for schizophrenia (26%), but less than for depression (42%;
(Schomerus et al., 2013)). Thus, it is no surprise that alcohol
use disorders are particularly stigmatized (Schomerus et al.,
2011), not only in Germany, and even in comparison with
depression and other mental disorders. This is consistent
with people with alcohol use disorders having the largest
treatment gap of any mental disorder (Alonso et al., 2004;
Kohn et al., 2004; Rehm et al., 2013b). Thus, a clearly di-
mensional concept such as heavy drinking over time may
help. Compared with other essentially dimensional concepts,
for example the number of DSM-5 (American Psychiatric
Association, 2013) criteria as an indicator of level of sever-
ity, heavy use over time is simpler to understand, and is not
per se associated with psychiatric problems, thus being more
suitable to reduce stigma than dimensional approaches based
on psychiatric diagnoses, like the DSM-5.
Nutt and Rehm (Nutt and Rehm, 2013) have recently laid
down an alternative approach to alcohol use disorders based
on heavy drinking, which would be analogous to blood pres-
sure. It stresses the continuous rather than dichotomous
nature of the heavy drinking measure. This is not to say, that
cutting down drinking or achieving abstinence is easy or a
matter of will only (in fact, the approach explicitly calls for
improving pharmacologically assisted interventions), but such
an approach will likely reduce stigma, as well as have pre-
ventive aspects, points put forward nearly 30 years ago by
the UK Royal College of General Practitioners in its report
‘Alcohol—a Balanced View’ (Anderson et al., 1986).
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Finally, Bradley and Rubinsky (2013) as others before (Li
et al., 2007) suggest to use heavy use over time as one of
several criteria for defining substance use disorders. Again,
such a more complex definition would be necessary, if the
combined definition could explain more relevant phenomena
or otherwise show better predictive power. This is an empir-
ical question. We have yet to be convinced of one important
phenomenon that cannot be explained by a ‘heavy use over
time’ definition, but that can be explained by a more compre-
hensive definition.
In conclusion, we believe that heavy use over time should
seriously be considered as the best definition for what is cur-
rently called substance use disorders or dependence. Of course,
since it is a continuum, thresholds will have to be set similar to
setting thresholds for raised blood pressure (which have
changed historically and are conditioned by treatment options
and concurrent diseases) or for many other diseases in ICD
(Rose, 1992). These seem to be common procedures and do
not preclude reimbursement of treatment or fall outside current
medical practice. When levels of use increase, more negative
consequences occur. However, the primary criterion should be
heavy use, because it also points in the direction of what can be
done to counter the negative consequences (which does not
mean that this is always easy, and should not be aided).
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